Company Overview - Suzhou Fengbei Biotechnology Co., Ltd. (Fengbei Bio) is preparing to list on the Shanghai Stock Exchange, aiming to raise 750 million yuan [2] - The company specializes in the comprehensive utilization of waste resources, primarily producing bio-based materials and biofuels from waste oils [4] Financial Performance - Fengbei Bio reported revenues of 1.71 billion yuan in 2022, 1.73 billion yuan in 2023, and projected 1.948 billion yuan in 2024, with net profits of 133 million yuan, 130 million yuan, and 124 million yuan respectively [4] - In the first half of 2025, the company achieved revenues of 1.478 billion yuan, a 49.62% increase from 988 million yuan in the same period of the previous year [7] - For the first nine months of 2025, Fengbei Bio expects revenues between 2.1 billion and 2.3 billion yuan, representing a growth of 51.40% to 65.82% compared to 1.387 billion yuan in the same period of 2024 [8] Shareholding Structure - Pingyuan controls 85.4% of Fengbei Bio, holding 59.78% directly and additional shares through subsidiaries [9] - Post-IPO, Pingyuan's shareholding will decrease to 44.82%, while other shareholders will hold smaller percentages [10] Project Financing - The current financing round will fund the construction of several projects, including an annual production capacity of 300,000 tons of oleic acid methyl ester and 50,000 tons of bio-diesel [3]

Core Viewpoint - The company, Fengbei Biological Technology Co., Ltd., is set to go public on the Shanghai Stock Exchange, aiming to raise 1 billion yuan for expansion projects in the waste oil resource utilization sector [1][3]. Financial Performance - The company has experienced declining revenue and net profit from 2022 to 2024, with revenues of 1.71 billion yuan, 1.73 billion yuan, and 1.95 billion yuan, and net profits of 135.92 million yuan, 123.04 million yuan, and 115.32 million yuan respectively, indicating a downward trend [3]. - The sales prices of the company's main products have also shown a downward trend during the same period [3][4][5]. Product Pricing - The sales prices for the company's biodiesel formulation products decreased from 0.77 million yuan/ton in 2022 to 0.61 million yuan/ton in 2024, while industrial-grade mixed oil prices fell from 0.91 million yuan/ton to 0.62 million yuan/ton [4]. - The sales prices for biofuels and oil chemical products also declined, with biofuels dropping from 0.98 million yuan/ton to 0.73 million yuan/ton, and oil chemical products from 1.18 million yuan/ton to 0.89 million yuan/ton [5]. Inventory and Liabilities - The company's inventory has been increasing, with values of 104.24 million yuan, 198.38 million yuan, and 242.01 million yuan from 2022 to 2024, indicating a growing stockpile [6]. - The raw materials, primarily waste oil and industrial-grade mixed oil, accounted for a rising proportion of total inventory, increasing from 30.77% in 2022 to 40.71% in 2024 [6]. - The company has a significant amount of current liabilities, with total current liabilities of 373.14 million yuan, 336.64 million yuan, and 358.53 million yuan over the same period, primarily consisting of short-term loans and accounts payable [7][8]. Legal Issues - The company is involved in ongoing litigation related to a fire incident at a leased facility, which resulted in significant inventory losses and subsequent lawsuits from various parties [10][11].

Core Viewpoint - Suzhou Fengbei Biotechnology Co., Ltd. has recently passed its IPO review and is preparing to list on the Sci-Tech Innovation Board, aiming to raise 750 million yuan [2][4]. Group 1: Company Overview - Fengbei Biotechnology focuses on the comprehensive utilization of waste resources, primarily converting waste oils into resource products [5]. - The company's main products include bio-based materials and biofuels, with applications in various sectors such as pesticides, fertilizers, and biomedicine [5]. Group 2: Financial Performance - The company's revenue for 2022, 2023, and projected for 2024 is 1.71 billion yuan, 1.73 billion yuan, and 1.948 billion yuan respectively, with net profits of 133 million yuan, 130 million yuan, and 124 million yuan [5]. - In the first half of 2025, Fengbei reported revenue of 1.478 billion yuan, a 49.62% increase from 988 million yuan in the same period last year, with a net profit of 85.06 million yuan, up 23.51% from 68.87 million yuan [8]. Group 3: IPO Details - The IPO is expected to raise 750 million yuan, which will be used for new projects including the annual production of 300,000 tons of oleic acid methyl ester and various agricultural microbial agents [3][4]. - The company has been in the IPO process for over two years, having submitted its prospectus on June 8, 2023 [4]. Group 4: Shareholding Structure - As of the IPO, Pingyuan controls 85.4% of Fengbei's shares, making it the controlling shareholder [9]. - Post-IPO, Pingyuan's shareholding will decrease to 44.82%, while other shareholders will hold the remaining shares [10].

Core Viewpoint - Suzhou Fengbei Biotechnology Co., Ltd. has received approval for its IPO application from the Shanghai Stock Exchange, indicating a positive outlook for the company's growth in the waste oil resource utilization sector [2]. Group 1: Company Overview - Fengbei Biotechnology is a high-tech enterprise focused on the comprehensive utilization of waste resources, primarily producing resource-based products from waste oil [4]. - The company's main business includes waste oil resource utilization, with secondary operations in oil chemical products [4]. - Key products include bio-based materials (such as pesticide and fertilizer additives) and biofuels (primarily biodiesel) [4]. Group 2: Financial Performance - The company's revenue for the reporting period was 1,708.69 million yuan, 1,727.78 million yuan, and 1,948.02 million yuan, showing a growth trend [6]. - The net profit attributable to the parent company was 135.92 million yuan, 123.04 million yuan, and 115.32 million yuan during the same periods, indicating a decline in profitability [6]. Group 3: Shareholding Structure - The controlling shareholder and actual controller of Fengbei Biotechnology is Pingyuan, who directly holds 59.78% of the shares and indirectly controls an additional 25.62% through other entities [5]. - Pingyuan holds a total of 85.40% of the company's shares and serves as the chairman [5]. Group 4: Key Questions from the Listing Committee - The listing committee raised questions regarding the company's customer and product structure adjustments for 2024, as well as the reasons for the decrease in sales and management expenses compared to 2023 [7]. - Concerns were also expressed about the sustainability of revenue from biofuels and the growth potential of industrial-grade mixed oil, along with the overall stability of the company's operating performance [7].

Core Viewpoint - The company, Suzhou Fengbei Biotechnology Co., Ltd., is set to undergo an IPO review by the Shanghai Stock Exchange, highlighting its leadership in the waste oil resource utilization sector amid a global push for green transformation [1] Group 1: Green Industry Chain - The company has established a complete and efficient green industry chain that transforms waste oil into biodiesel and bio-based materials, addressing environmental concerns while creating high-value products [2] - The biodiesel segment has seen significant success, with the company overcoming technical challenges to develop low pour point biodiesel, enhancing market applicability in colder regions [2] Group 2: Bio-based Materials - The company has made substantial advancements in bio-based materials, applying them across various sectors such as agriculture, mining, inks, textiles, and biomedicine, achieving commercial success [3] - In the agricultural sector, the company holds a leading market share in bio-diesel formulations and collaborates closely with major industry players [3] Group 3: Innovation and R&D - The company emphasizes innovation as a core driver of growth, with significant investments in R&D leading to 144 patents, including domestic and international inventions [4] - The establishment of research centers has attracted top talent, focusing on new methods for waste oil utilization and the development of superior bio-based materials [4] Group 4: Industry Recognition - The company's R&D achievements have garnered industry accolades, including recognition as an excellent pesticide additive supplier and various innovation awards, underscoring its leadership in green technology [5] Group 5: Policy Support and Market Opportunities - National policies support the company's green development, encouraging the production of biodiesel from waste oil, which aligns with the company's strategic adjustments and increased R&D investments [6][7] - The company has formed strategic partnerships to explore new market applications for biodiesel, responding to government initiatives and enhancing its competitive edge [7] Group 6: Future Outlook - With a growing global emphasis on sustainability, the demand for biofuels and bio-based materials is expected to rise, prompting the company to continue its commitment to green development and innovation [7]

Summary of Upcoming IPOs - A total of 4 companies are scheduled for IPO review from August 4 to August 8, aiming to raise a combined total of 1.912 billion yuan [1][2]. Company Details Zhongcheng Consulting - Planned fundraising was reduced from 330 million yuan to 200 million yuan, with the removal of EPC business expansion and liquidity support projects [3][13]. - The company specializes in engineering cost consulting, bidding agency, project supervision, and management services [13][14]. Fengbei Biological - The fundraising target was cut from 1 billion yuan to 750 million yuan, eliminating liquidity support projects [7][18]. - The company focuses on the comprehensive utilization of waste oil resources, producing bio-based materials and biofuels [18][19]. Jieke Co., Ltd. - The planned fundraising decreased from 750 million yuan to 676 million yuan, with adjustments made to the funding for the intelligent robot production project and the removal of liquidity support [10][23]. - The company is engaged in the research, production, and sales of collaborative robot products, with applications in various high-tech fields [23][24]. Nante Technology - The fundraising target was reduced from 420 million yuan to 286 million yuan, with the removal of certain expansion projects and adjustments to funding for other projects [12][27]. - The company specializes in the research, production, and sales of precision mechanical components [27][28]. Financial Performance Overview - Zhongcheng Consulting reported total assets of approximately 602.75 million yuan and a net profit of 105.39 million yuan for the year ending December 31, 2024 [17]. - Fengbei Biological's total assets reached approximately 1.236 billion yuan, with a net profit of 123.82 million yuan for the same period [21]. - Jieke Co., Ltd. reported total assets of approximately 104.67 million yuan and a net profit of 622,800 yuan for the year ending December 31, 2024 [25]. - Nante Technology's total assets were approximately 1.417 billion yuan, with a net profit of 98.22 million yuan for the same period [29]. Fundraising Projects Zhongcheng Consulting - Major projects include engineering consulting service network construction and R&D and information technology projects, with a total investment of 1.299 billion yuan [18]. Fengbei Biological - Key projects include the construction of a facility for producing 300,000 tons of oleic acid methyl ester and other bio-based products, with a total investment of 1.04 billion yuan [22]. Jieke Co., Ltd. - The company plans to invest in projects related to the production of collaborative robots and R&D center construction, with a total investment of approximately 754.31 million yuan [26]. Nante Technology - The company is focusing on precision component production and expansion projects, with a total investment of approximately 501.42 million yuan [31].